Exchange: NASDAQ·Updated 10:33 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 14Pre-Market

Estimated EPS

-$0.11

Estimated Rev

$1.33M

$NRXP Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 88.24% YoY • Reported revenue of $1.07M • NRX Pharmaceuticals expects to incur operating losses through 2026, anticipating incremental revenue from clinical operations and pharmaceutical product sales upon regulatory approval. The company secured capital to fund drug development through Q3 2026 for NDA submissions.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.11
-$0.15
-40.77%
MISSED
Q1 '26
$0.21
-$0.04
-119.14%
MISSED
Q4 '25
-$0.07
--
--
N/A
Q3 '25
-$0.13
-$0.27
-107.69%
MISSED
Q2 '25
-$0.15
-$0.98
-552.68%
MISSED

Advertisement|Remove ads.